This Week in Ophthalmology: Week of October 26, 2024

Author(s):

Key Takeaways

Dr. John Berdahl discussed clinical trials of travoprost, highlighting its potential impact on ophthalmic treatments.
Meghan Berkenstock analyzed uveitis incidence and prevalence using the US TriNetX Database, emphasizing associated ocular complications.
Dr. Michael Singer compared chloroprocaine ophthalmic gel to traditional drops for anesthesia in intravitreal injections, revealing significant findings.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

News from the American Academy of Ophthalmology’s recent annual meeting in Chicago continues to be a hot topic of discussion. This week, we will visit some interesting discussions Sheryl Stevenson and I had with leading KOLs during the conference.

First, let’s take a look at our discussion with Dr. John Berdahl of Vance Thompson Vision, who discusses the clinical trials of travoprost.

Watch: AAO 2024: Clinical trials of travoprost

Next, we discussed Incidence and prevalence of uveitis and associated ocular complications in the US TriNetX Database with Meghan Berkenstockan associate professor of ophthalmology at the Wilmer Eye Institute.

Watch: AAO 2024: Incidence and prevalence of uveitis and associated ocular complications in the US TriNetX Database

We also talked to Dr. Michael Singer, director of clinical research, Medical Center Ophthalmology Associates, shared insights on the results of research on the effectiveness of gel versus traditional drops as anesthesia for intravitreal injections.